Biotech Matters – Details, episodes & analysis

Podcast details

Technical and general information from the podcast's RSS feed.

Biotech Matters

Bluestar BioAdvisors

Science

Frequency: 1 episode/122d. Total Eps: 7

Bluestar BioAdvisors team shares insights on drug pipelines and predicts industry trends. Each episode is hosted by a senior member of our New York City based life sciences consulting firm. The host is typically joined by an external expert guest, with whom the host expands on their experiences providing insights and recommendations for industry leaders and emergent innovators, and translating the data of today into the implications for business of science of tomorrow.

Read moreCollapse

Site

RSS

Apple

Data updated on 04/07/2026

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Apple Podcasts

Spotify

No recent rankings available

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

https://bluestarbioadvisors.com/team/jeffrey-fineberg#bio
4 shares
https://bluestarbioadvisors.com
3 shares
https://glomerularcenter.org/
2 shares

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736
1 share

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

RSS feed quality

To improve

Score global : 63%

Publication history

Monthly episode publishing history over the past years.

Year

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

Ep. 7 - Heading to Houston: What We're Looking Forward to at ASN Kidney Week 2025 (with Dr. Pietro Canetta)

Episode 7

Monday, November 3, 2025 • Duration 46:54

Bluestar is once again heading to ASN Kidney Week, this time in Houston, TX. Since our last episode, Otsuka, the manufacturer of sibeprenlimab, announced that the FDA has granted Priority Review of their BLA application; its PDUFA date is November 28th of this year. Additionally, Vera Therapeutics, the manufacturer of atacicept put out a press release this past summer that the ORIGIN Phase 3 trial met its primary endpoint of reduction in proteinuria (UPCR); participants receiving atacicept achieved a 46% reduction from baseline, and 42% reduction compared to placebo at week 36 (p<0.0001). Vera plans to submit the BLA for atacicept in 2025, which may allow for a commercial launch in 2026. And these are just the recent developments in IgAN. Travere Therapeutics, manufacturer of FILSPARI (sparsentan) presented data from their FSGS trial – DUPLEX – at Kidney Week 2023 in Philadelphia. In contrast to the contemporaneous PROTECT study in IgAN, DUPLEX did not meet the primary endpoint. Subsequently, Travere has worked with an FDA advisory committee, reanalyzed the trial data, and announced last month that it has filed a sNDA for approval in FSGS; the PDUFA date is January 13th, 2026.

After the 2023 conference, Dr. Pietro Canetta joined Bluestar Principal Jeff Fineberg on the Biotech Matters podcast to talk about all things IgAN, as well as the two FILSPARI trials and the data presented at the conference. So, it's only fitting that Dr. Canetta is back on the podcast to revisit that conversation, discuss what has happened in the two years since, and tell us what he's most looking forward to at this year's conference.

Where to find Dr. Canetta:

Columbia University Glomerular Center

Where to learn more:

Columbia CME Courses

Glomerular Disease-Focused CME Course

Topics and Timestamps

00:00 - Intro + recap
04:00 - Reflection on Filspari in FSGS; implications for UPCR in FSGS and other diseases going forward
12:40 - DKD: better/newer surrogate endpoints; matching patients to the right Tx
19:30 - IgAN: the 4-hit model of disease and the role of B cells
22:45 - Where do B cell-targeting therapies fit in the evolving IgAN Tx Paradigm?
26:45 - The counter argument to using Bcells early in IgAN treatment
30:10 - Bcells beyond IgAN: Lupus Nephritis and other glomerular diseases
33:00 - Different B cell-targeting mechanisms for different glomerular diseases and/or heterogeneous patient populations
36:45 - A homecoming for complement inhibitor therapies
42:00 - Other recommended sessions at Kidney Week 2025
45:00 - Where to learn more from Dr. Canetta

Read moreCollapse

Ep. 6 - B-cells vs. Complement in IgAN: A Look at the Data from Kidney Week 2024 (with Dr. Vlado Perkovic)

Episode 6

Monday, December 9, 2024 • Duration 30:34

Principal Jeff Fineberg, PhD sits down with Vlado Perkovic, MBBS, PhD, to discuss the IgA nephropathy trial data presented at Kidney Week 2024 in San Diego. Jeff begins by asking Dr. Perkovic to talk about why targeting B-cells is an attractive target, and why BAFF/APRIL might prove more promising than CD20. The two then discuss the data with two agents in development for the treatment of IgAN, atacicept (targeting BAFF/APRIL) and sibeprenlimab (targeting APRIL only). The conversation then pivots to the prospect of complement inhibition with FABHALTA® (iptacopan) in IgA nephropathy, including a comparison of the strategy to target certain complement factors/pathways over others in IgAN. Finally, the discussion takes a broader lens to the evolving IgAN treatment landscape, that may include both of these novel therapeutic mechanisms, in addition to recently approved drugs FILSPARI® (sparsentan) and TARPEYO® (budesonide), as well as other CKD therapeutic classes, such as SGLT2 inhibitors and GLP-1 receptor agonists.

Vlado Perkovic Bio

Vlado Perkovic is the Provost at UNSW Sydney and Scientia Professor at UNSW, and was previously the Dean of the Faculty of Medicine and Health as well as Professorial Fellow at The George Institute, Australia, and a Staff Specialist in Nephrology at the Royal North Shore Hospital. His research focus is clinical trials and epidemiology, in particular, in preventing the progression of kidney disease and its complications. He leads several major international clinical trials with a focus on diabetic kidney disease, IgA nephropathy and CKD more broadly, and has Chaired the Steering Committees of many trials including CREDENCE, FLOW, TESTING, PROTECT, and APPLAUSE, along with several ongoing trials.

Dr. Perkovic holds a Doctor of Philosophy from the University of Melbourne and is a Fellow of the Royal Australasian College of Physicians, of the Australian Academy of Health and Medical Sciences, and of the American Society of Nephrology.

Ep. 5 - It's ASN Kidney Week 2024! Here's What We're Excited About (with Dr. Beatrice Goilav)

Episode 5

Monday, October 21, 2024 • Duration 18:03

Principal Jeff Fineberg, PhD welcomes back returning guest nephrologist Beatrice Goilav, MD, to discuss the program featured at Kidney Week 2024 in San Diego.

Dr. Goilav reflects on what has happened in the field since last year's Kidney Week conference, as well as her hopes for what will be presented at a variety of sessions, including more data in IgA nephropathy, lupus nephritis, and FSGS. She also offers her perspective on the newest advancements with complement inhibitors in glomerular diseases – including approval of FABHALTA® (iptacopan) in IgA nephropathy – as well as recommendations for educational symposia and scientific sessions on the topic. Finally, she and Jeff discuss GLP-1 receptor agonists, and what this class of drug may mean for the management of CKD.

Dr. Goilav hangs out on the social network X. Her handle is @BGoilav, and her DM is open to listeners with follow-on questions.

For more information about Bluestar BioAdvisors, please visit our website.

Read moreCollapse

Ep. 4 - ADC Alchemy: A Post-ASCO Discussion

Episode 4

Thursday, July 25, 2024 • Duration 12:53

Bluestar Managing Director Erin Olsen is back from the ASCO conference in Chicago and joins Principal Jeff Fineberg on the podcast again, this time to talk about all things antibody drug conjugates (ADCs) in oncology.

Given the number and value of deals in this space over the past couple of years, as well as the 170+ ADCs now in clinical development, Jeff asks Erin to take stock of what we've learned about the potential of these molecules, with all their moving parts, and opine on what lies ahead.

Over the course of this brief conversation, Erin and Jeff touch on some key questions about ADCs, including:

• Are ADCs living up to their promise? (1:48)
• What are some lessons learned from Enhertu? (3:20)
• What have we learned about TOP1 payloads and TROP2 targeting? (6:10)
• Have ADCs delivered on better safety than chemo? (8:40)
• What's next for ADCs? (10:50)

Bluestar BioAdvisors LLC is a boutique consulting firm comprised of strategic experts in the business of life sciences. We help clients answer key strategic questions about asset value, positioning, and future market potential, serving as an independent, objective advisor through the critical decision-making points of portfolio planning and business development.

For more information about us, please visit Bluestar BioAdvisors' website, Erin's bio, and Jeff's bio.

Read moreCollapse

Ep.3 What We're Watching at ASCO 2024

Episode 3

Thursday, May 30, 2024 • Duration 17:01

As the Bluestar team prepares to head to ASCO 2024 this upcoming weekend, Bluestar Principal Jeff Fineberg sits down with Bluestar Managing Director Erin Olsen to talk about interesting abstracts related to two topics:

What are the unmet needs in 1L therapy?
The KRAS G12C mutation landscape

Read moreCollapse

Ep. 2 - Making Sense of the Latest IgAN Trials (with Dr. Pietro Canetta)

Episode 2

Wednesday, December 6, 2023 • Duration 39:09

After attending ASN Kidney Week, Bluestar Principal Jeff Fineberg sits down with Dr. Pietro Canetta to talk all things IgA nephropathy (IgAN). After Dr. Canetta provides a brief summary of his IgAN lecture at Kidney Week, Emerging Therapeutic Options in IgA Nephropathy, the two discuss the Filspari (sparsentan) data presented from both the PROTECT study, in IgAN, the DUPLEX study, in FSGS. From there, Dr. Canetta opines on the value of surrogate endpoints in predicting the three D's of CKD: death, dialysis, and doubling of serum creatinine (SCr). Dr. Canetta briefly discusses Novartis' press release announcing the positive Phase II data with atrasentan, another ETA RA, before the conversation shifts to other drug classes and therapeutic targets, including SGLT2 inhibitors, and B-cell activation (i.e., APRIL/BAFF). Finally, Jeff asks Dr. Canetta about whether the recent advancements in IgAN are generalizable to other glomerular diseases, and what might be the determinants of this.

Jump to specific topics in the conversation:

00:00 Recap + guest intro/bio + Kidney Week lecture summary
05:05 Filspari (sparsentan) trial results from PROTECT (IgAN) and DUPLEX (FSGS)
12:25 Value of surrogate endpoints in predicting three D's - death, dialysis, and doubling of SCr - in glomerular disease
19:55 Atrasentan press release
23:05 The "four-hit" hypothesis of IgAN pathogenesis and SGLT2i
26:10 B-cell activation (APRIL/BAFF) as a therapeutic approach in IgAN
31:55 Generalizability (and lack thereof) of therapeutic approaches to other glomerular diseases
37:25 Where to learn more

Helpful links:

PROTECT Study (Filspari/sparsentan in IgAN)

DUPLEX Study (Filspari/sparsentan in FSGS)

Novartis press release (atrasentan in IgAN)

Ep. 1 - What We're Looking for at ASN Kidney Week 2023: A Conversation with Dr. Beatrice Goilav

Episode 1

Wednesday, November 1, 2023 • Duration 27:31

In the first ever Biotech Matters podcast episode, Principal Jeff Fineberg, PhD, sits down with nephrologist Beatrice Goilav, MD, to talk all things Kidney Week. Dr. Goilav offers her thoughts on an ideal day-by-day itinerary, as well as her hopes for what will be presented at a variety of sessions, including drug trials in IgAN, and new studies of SGLT2 inhibitors. She also offers her perspective on the potential for complement inhibitors in glomerular diseases, and which of these drugs in development she is most interested in. Finally, she makes some recommendations on poster abstracts to visit in the exhibit hall.

For more information about Bluestar BioAdvisors, please visit our website.

Dr. Goilav hangs out on X (formerly known as Twitter) @BGoilav. Her DM is open to episode listeners with follow-on questions.

Read moreCollapse

Biotech Matters – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Related Shows Based on Content Similarities

Biotech Matters – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

Other10

The Lancet1

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Related Shows Based on Content Similarities

Other10

The Lancet1